NM
TEVA icon

NWI Management’s Teva Pharmaceuticals TEVA Stock Holding History

NWI Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Sell
40,000
-2,025,000
-98% -$67.4M 0.06% 50
2026
Q1 		$62.2M Hold
2,065,000
– – 3.54% 8
2025
Q4 		$64.4M Hold
2,065,000
– – 2.97% 10
2025
Q3 		$41.7M Hold
2,065,000
– – 2.22% 14
2025
Q2 		$34.6M Buy
2,065,000
+405,000
+24% +$6.54M 1.79% 18
2025
Q1 		$25.5M Buy
1,660,000
+940,000
+131% +$16.8M 3.21% 11
2024
Q4 		$15.9M Buy
+720,000
New +$13.1M 0.7% 26

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

NWI Management's TEVA Position: Q2 2026 in Review

NWI Management reduced its Teva Pharmaceuticals (TEVA) stake by 98% in Q2 2026, selling an estimated $67.4M and leaving 40,000 shares worth $1.35M. The position accounts for 0.06% of the portfolio, ranked #50.

NWI Management first reported a position in TEVA in Q4 2024 and has held it in 7 quarters since. The position peaked at $64.4M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • NWI Management held 40,000 shares of Teva Pharmaceuticals worth $1.35M as of Q2 2026.
  • NWI Management sold 2,025,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $67.4M.
  • Teva Pharmaceuticals made up 0.06% of NWI Management's portfolio in Q2 2026, its #50 holding.
  • NWI Management first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • NWI Management's Teva Pharmaceuticals position peaked at $64.4M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on NWI Management's 13F filing for Q2 2026, filed 14 Aug 2026.